By Genetic Engineering & Biotechnology News (GEN) | August 3, 2026
Receptor.AI and Sethera partner to create a closed-loop drug discovery workflow. Sethera will generate and experimentally screen architecture-diverse polymacrocyclic peptide libraries. Receptor.AI will apply physics-based modeling, artificial intelligence, and multiparameter optimization to interpret sequence, architecture, enrichment, and activity data; develop binding hypotheses; prioritize candidate series; and guide focused optimization cycles.
Subsequently, the companies will design, synthesize, and experimentally test new candidates, using the resulting data to inform each subsequent cycle.